Insurance Delays and Denials Mean Kids Don’t Get Allergy and Asthma Medications

A new study presented at the ACAAI meeting reveals that 40% of insurance requests for pediatric biologic medications are denied. These delays in the prior authorization process often leave children with uncontrolled asthma and allergies for weeks.
Why it matters
The findings highlight systemic barriers in the healthcare system that prevent children from accessing necessary, life-improving treatments.
New study finds about 4 in 10 requests for children’s biologic medications were denied
PHOENIX (Nov. 12, 2026) – When a child’s severe asthma , eczema , hives, or food allergy isn’t under control, an allergist may prescribe a newer type of medicine called a biologic. But a new study being presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2026 Annual Scientific Meeting finds that getting insurance to pay for these medicines can take weeks, and many requests are turned down.
Biologics are medicines, usually given as shots, that target the part of the immune system that causes allergic disease. They can help children whose symptoms don’t get better with other treatments. Before insurance will pay for a biologic, a doctor’s office usually must get prior authorization – requesting permission from the insurance company to order the medication.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in